WO2012082573A1 - Procédés prédictifs et procédés de traitement de l'arthrite en utilisant des antagonistes de l'il-17 - Google Patents

Procédés prédictifs et procédés de traitement de l'arthrite en utilisant des antagonistes de l'il-17 Download PDF

Info

Publication number
WO2012082573A1
WO2012082573A1 PCT/US2011/064307 US2011064307W WO2012082573A1 WO 2012082573 A1 WO2012082573 A1 WO 2012082573A1 US 2011064307 W US2011064307 W US 2011064307W WO 2012082573 A1 WO2012082573 A1 WO 2012082573A1
Authority
WO
WIPO (PCT)
Prior art keywords
patient
allele
antagonist
hla
treatment
Prior art date
Application number
PCT/US2011/064307
Other languages
English (en)
Inventor
Charles Paulding
Ying Wang
Timothy Wright
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2012082573A1 publication Critical patent/WO2012082573A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the IL-17 antagonist is selected from the group consisting of: a) secukinumab; b) an IL-17 antibody that binds to an epitope of IL-17 comprising Leu74, Tyr85, His86, Met87, Asn88, Val l24, Thrl25, Prol26, Ilel27, Vall28, Hisl29; c) an IL- 17 antibody that binds to an epitope of IL-17 comprising Tyr43, Tyr44, Arg46, Ala79, Asp80; d) an IL-17 antibody that binds to an epitope of an IL-17 homodimer having two mature IL-17 protein chains, said epitope comprising Leu74, Tyr85, His86, Met87, Asn88, Val l24, Thrl 25, Prol26, Ilel27, Vall28, His l29 on one chain and Tyr43, Tyr44, Arg46, Ala79, Asp80 on the other chain; e) an IL- 17 antibody
  • active rheumatoid arthritis or “active RA” is used to mean RA with visible signs and symptoms (e.g., swelling, difficulty in flexion, etc.).
  • a set of parameters may be the Blosum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.
  • the percent identity between two amino acid or nucleotide sequences can also be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4:1 1-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
  • ACR/EULAR criteria (found in Aletaha et al. (2010) Ann. Rheum. Dis. 69:1580-1588) may be used to classify a patient as having RA.
  • Secukinumab (see, e.g., WO2006/013107 and WO2007/1 17749) has a very high affinity for IL- 17, i.e., a KD of about 100-200 pM and an IC 50 for in vitro neutralization of the biological activity of about 0.67 nM human IL-17A of about 0.4 nM.
  • secukinumab inhibits antigen at a molar ratio of about 1 :1.
  • This high binding affinity makes the secukinumab antibody particularly suitable for therapeutic applications.
  • secukinumab has a very long half life, i.e., about 4 weeks, which allows for prolonged periods between administration, an exceptional property when treating chronic life-long disorders, such as rheumatiod arthritis (RA).
  • RA chronic life-long disorders
  • Direct labels include fluorescent or luminescent tags, metals, dyes, radionucleides, and the like, attached to the antibody.
  • Indirect labels include various enzymes well known in the art, such as alkaline phosphatase, hydrogen peroxidase and the like.
  • polypeptide products of HLA-DRB1 *04 and/or HLA-DRB1 *SE alleles are immobilized and incubated with a labeled antibody.
  • the labeled antibody binds to the immobilized target molecule. After washing to remove unbound molecules, the sample is assayed for the presence of the label.
  • IL-17 antagonists for use in treating RA, characterized in that: a) a biological sample from an RA patient is assayed for the presence or absence of a SE; and b) a therapeutically effective amount of an IL-17 antagonist is administered to the RA patient if the biological sample has the presence of the at least one allele.
  • PG pharmacogenetic
  • Table 7 shows the DAS28 CRP score change and percent of patients reaching ACR20, or ACR50 at week 12 and week 16 by carrier/non-carrier and treatment (placebo, 25 mg, 75 mg, 150 mg or 300 mg secukinumab) in patients who had not previously been treated with secukinumab.
  • Table 11 shows the percent of secukinumab-treated patients reaching a given endpoint (ACR20, ACR50, ACR70).
  • HLA-DRB 1 *04- patients with no HLA-DRB 1 *04 allele;
  • HLA-DRB 1 *04 + patients with at least one HLA- DRB 1 *04 allele.
  • the data provided herein supports an association between HLA-DRB 1 *04 and/or HLA-DRB1 *SE status and RA patient's response to secukinumab, as measured by DAS28 and ACR scores.
  • This finding is currently undergoing validation in prospective clinical trials.
  • the SE does not predict response to biological agents, particularly to anti-TNF factor treatments such as etanercept and infliximab (Potter et al. (2009) Ann. Rheum. Dis. 68:69-74). Potter et al showed that there was no association between anti-TNF response and carriage of risk alleles for either of the two well established RA susceptibility factors, SE or PTPN22.
  • our determination that there is a significant association between HLA-DRB 1 *04 and/or HLA-DRB l *SE status and RA patient's response to secukinumab is surprising.

Abstract

L'invention concerne des procédés prédictifs innovants et des thérapies personnalisées pour traiter l'arthrite rhumatoïde (RA). Spécifiquement, l'invention consiste à prédire la probabilité qu'un patient atteint de RA répondra cliniquement à un traitement avec une molécule liant l'IL-17, par ex. un anticorps contre l'IL-17 comme le secukinumab.
PCT/US2011/064307 2010-12-13 2011-12-12 Procédés prédictifs et procédés de traitement de l'arthrite en utilisant des antagonistes de l'il-17 WO2012082573A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42252110P 2010-12-13 2010-12-13
US61/422,521 2010-12-13

Publications (1)

Publication Number Publication Date
WO2012082573A1 true WO2012082573A1 (fr) 2012-06-21

Family

ID=45390221

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/064307 WO2012082573A1 (fr) 2010-12-13 2011-12-12 Procédés prédictifs et procédés de traitement de l'arthrite en utilisant des antagonistes de l'il-17

Country Status (3)

Country Link
AR (1) AR084234A1 (fr)
TW (1) TW201307845A (fr)
WO (1) WO2012082573A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013077907A1 (fr) * 2011-11-21 2013-05-30 Novartis Ag Procédés de traitement du rhumatisme psoriasique (psa) utilisant des antagonistes d'il-17 et des allèles répondeurs ou non répondeurs à psa
EP2635303A2 (fr) * 2010-11-05 2013-09-11 Novartis AG Méthodes de traitement de la polyarthrite rhumatoïde au moyen d'antagonistes d'il-17
WO2014036357A1 (fr) * 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Méthodes de traitement de pathologies par des anticorps qui se lient au récepteur du facteur stimulant les colonies 1 (csf1r)
US8747845B2 (en) 2010-05-04 2014-06-10 Five Prime Therapeutics, Inc. Methods of treatment by administering antibodies that bind colony stimulating factor 1 receptor (CSF1R)
WO2014155278A2 (fr) 2013-03-26 2014-10-02 Novartis Ag Méthodes de traitement de maladies auto-immunes à l'aide d'antagonistes de l'il -17
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
WO2016038538A1 (fr) * 2014-09-10 2016-03-17 Novartis Ag Utilisation d'antagonistes d'il-17 pour inhiber la progression d'une lésion structurelle chez des patients atteints d'une polyarthrite psoriasique
US9765147B2 (en) 2014-10-29 2017-09-19 Five Prime Therapeutics, Inc. Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
US10040858B2 (en) 2014-12-22 2018-08-07 Five Prime Therapeutics, Inc. Anti-CSF1R antibodies for treating PVNS
US10975153B2 (en) 2014-06-23 2021-04-13 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
US10982001B2 (en) 2012-05-11 2021-04-20 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
CN114249826A (zh) * 2014-12-22 2022-03-29 诺华股份有限公司 Il-17抗体中半胱氨酸残基的选择性还原
US11421034B2 (en) 2017-09-13 2022-08-23 Five Prime Therapeutics, Inc. Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer
US11559583B2 (en) 2015-04-13 2023-01-24 Five Prime Therapeutics, Inc. Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974701B2 (en) 2003-03-21 2005-12-13 Hemovations, Llc Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same
WO2006013107A1 (fr) 2004-08-05 2006-02-09 Novartis Ag Anticorps antagonistes de il-17
WO2007117749A2 (fr) 2006-01-31 2007-10-18 Novartis Ag Anticorps antagonistes il-17
WO2010034443A1 (fr) * 2008-09-29 2010-04-01 F. Hoffmann-La Roche Ag Anticorps contre l'il 17 humaine et utilisations associees

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974701B2 (en) 2003-03-21 2005-12-13 Hemovations, Llc Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same
WO2006013107A1 (fr) 2004-08-05 2006-02-09 Novartis Ag Anticorps antagonistes de il-17
WO2007117749A2 (fr) 2006-01-31 2007-10-18 Novartis Ag Anticorps antagonistes il-17
WO2010034443A1 (fr) * 2008-09-29 2010-04-01 F. Hoffmann-La Roche Ag Anticorps contre l'il 17 humaine et utilisations associees

Non-Patent Citations (45)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Molecular Biology", 1989, JOHN WILEY & SONS, pages: 6.3.1 - 6.3.6
"Promega Protocols and Applications Guide, Second Edition,", 1991, PROMEGA CORPORATION, pages: 263
ALETAHA ET AL., ANN. RHEUM. DIS., vol. 69, 2010, pages 1580 - 1588
ALETAHA ET AL., ANN. RHEUM. DIS., vol. 69, 2010, pages 1580 - 88
ALTSHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
BEGOVICH ET AL., J. IMMUNOLOGY, vol. 148, 1992, pages 249 - 58
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
BUTT, W. R.,: "Practical Immunology", 1984, MARCEL DEKKER
D. E. DE ALMEIDA ET AL: "Immune Dysregulation by the Rheumatoid Arthritis Shared Epitope", THE JOURNAL OF IMMUNOLOGY, vol. 185, no. 3, 30 June 2010 (2010-06-30), pages 1927 - 1934, XP055019689, ISSN: 0022-1767, DOI: 10.4049/jimmunol.0904002 *
DE ALMEIDA ET AL., J. IMMUNOL, vol. 185, 2010, pages 1927 - 34
DE VRIES ET AL., J. AUTOIMMUNITY, vol. 25, 2005, pages 21 - 25
E. MEYERS; W. MILLER, CABIOS, vol. 4, 1989, pages 11 - 17
FEITSMA ET AL., ARTHRITIS AND RHEUM., vol. 62, 2010, pages 117 - 25
FELSON ET AL., ARTHRITIS RHEUM, vol. 38, no. 6, 1995, pages 727 - 35
FISCHBACH; DUNNING: "A Manual of Laboratory and Diagnositc Tests(8th Edition)", 2009, WOLTERS KLUWER/LIPPINCOTT WILLIAMS AND WILLIAMS
FRANSEN ET AL., ANN RHEUM DIS, vol. 62, no. 1, 2003, pages 10
FRIES ET AL., ARTHRITIS AND RHEUMATISM, vol. 46, 2002, pages 2320 - 29
GONZALEZ-GAY ET AL., SEM. ARTHRITIS. RHEUM., vol. 31, 2002, pages 355 - 60
GORMAN; CRISWELL, GENETICS, vol. 28, 2002, pages 59 - 77
GREGERSEN ET AL., ARTHRITIS RHEUM., vol. 30, 1987, pages 1205 - 13
HOLOSHITZ, CURRENT OPINION IN RHEUMATOLOGY, vol. 22, 2010, pages 293 - 298
HOLOSHITZ, URRENT OPINION IN RHEUMATOLOGY, vol. 22, 2010, pages 293 - 298
HOWELL ET AL., J CLIN PATHOL 2010, vol. 63, 2009, pages 387 - 390
HUEBER ET AL., SCI. TRANSL. MED., vol. 2, no. 52, 2010, pages 52 - 72
HUEBER WOLFGANG ET AL: "Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis", SCIENCE TRANSLATION MEDICINE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 2, no. 52 / Article No.: 52ra72, 1 October 2010 (2010-10-01), pages 1 - 9, XP009155660, ISSN: 1946-6234 *
HUSTON ET AL., PROC. NATL. ACAD. SCI., vol. 85, 1988, pages 5879 - 5883
HWANG ET AL., ARTHRITIS RES THER, vol. 6, 2004, pages RI20 - 128
J. IMBODEN, ANNU. REV. PATHOL. MECH. DIS., vol. 4, 2009, pages 417 - 34
KABAT E.A. ET AL.: "Sequences of Proteins of Immunological Interest", NATIONAL INSTITUTE OF HEALTH
M. KHRAISHI, J. RHEUMATOL, vol. 82, 2009, pages 25 - 32
MARSH ET AL., BONE MARROW TRANSPLANTATION, vol. 45, 2010, pages 846 - 8
MARSH ET AL., TISSUE ANTIGENS, vol. 75, 2010, pages 291 - 455
MEYERS ET AL., COMPUT. APPL. BIOSCI., vol. 4, 1988, pages 11 - 17
MILLER ET AL., BR MED J (CLIN RES ED, vol. 286, no. 6361, 1983, pages 266
MOSELEY; BULL, CLIN. LAB HAEMATOL., vol. 4, 1982, pages 169 - 78
NEEDLEMAN ET AL., J. MOL. BIOL., vol. 48, 1970, pages 444 - 453
POTTER ET AL., ANN. RHEUM. DIS., vol. 68, 2009, pages 69 - 74
PREVOO ET AL., ARTHRITIS RHEUM, vol. 38, no. 1, 1995, pages 44 - 48
SALLIOT ET AL., ANN. RHEUM. DIS., vol. 68, 2009, pages 25 - 32
SAMBROOK ET AL.: "Molecular Cloning, A Laboratory Manual", vol. 3, 1989, COLD SPRING HARBOR LABORATORY
SHENDURE J.; JI, H., NATURE BIOTECHNOLOGY, vol. 26, no. 10, 1998, pages 1135 - 1145
T. E. CREIGHTON: "Proteins: Structure and Molecular Properties", 1983, W. H. FREEMAN & CO., pages: 79 - 86
VAN DER HELM-VAN MIL ET AL., ARTHRITIS AND RHEUM., vol. 54, 2006, pages 1117 - 21
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
WETTELAND PET, J. INTERN. MED., vol. 240, no. 3, 1996, pages 125 - 310

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200075B2 (en) 2010-05-04 2015-12-01 Five Prime Therapeutics, Inc. Nucleic acids encoding antibodies that bind colony stimulating factor 1 receptor (CSF1R)
US10562970B2 (en) 2010-05-04 2020-02-18 Five Prime Therapeutics, Inc. Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
US8747845B2 (en) 2010-05-04 2014-06-10 Five Prime Therapeutics, Inc. Methods of treatment by administering antibodies that bind colony stimulating factor 1 receptor (CSF1R)
US9957327B2 (en) 2010-05-04 2018-05-01 Five Prime Therapeutics, Inc. Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
US9695243B2 (en) 2010-05-04 2017-07-04 Five Prime Therapeutics, Inc. Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
US11186646B2 (en) 2010-05-04 2021-11-30 Five Prime Therapeutics, Inc. Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
EP2635303A2 (fr) * 2010-11-05 2013-09-11 Novartis AG Méthodes de traitement de la polyarthrite rhumatoïde au moyen d'antagonistes d'il-17
US10363307B2 (en) 2010-11-05 2019-07-30 Novartis Ag Methods of treating psoriatic arthritis using IL-17 antagonists
US11534491B2 (en) 2010-11-05 2022-12-27 Novartis Ag Methods of treating ankylosing spondylitis using IL-17 antagonists
US9744234B2 (en) 2010-11-05 2017-08-29 Novartis Ag Methods of treating ankylosing spondylitis using IL-17 antagonists
WO2013077907A1 (fr) * 2011-11-21 2013-05-30 Novartis Ag Procédés de traitement du rhumatisme psoriasique (psa) utilisant des antagonistes d'il-17 et des allèles répondeurs ou non répondeurs à psa
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
US10982001B2 (en) 2012-05-11 2021-04-20 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
CN104684582A (zh) * 2012-08-31 2015-06-03 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
RU2718751C2 (ru) * 2012-08-31 2020-04-14 Файв Прайм Терапьютикс, Инк. Способы лечения патологических состояний антителами, которые связываются с рецептором колониестимулирующего фактора 1 (csf1r)
US10221243B2 (en) 2012-08-31 2019-03-05 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
WO2014036357A1 (fr) * 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Méthodes de traitement de pathologies par des anticorps qui se lient au récepteur du facteur stimulant les colonies 1 (csf1r)
US10822421B2 (en) 2012-08-31 2020-11-03 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
WO2014155278A2 (fr) 2013-03-26 2014-10-02 Novartis Ag Méthodes de traitement de maladies auto-immunes à l'aide d'antagonistes de l'il -17
US10975153B2 (en) 2014-06-23 2021-04-13 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
WO2016038538A1 (fr) * 2014-09-10 2016-03-17 Novartis Ag Utilisation d'antagonistes d'il-17 pour inhiber la progression d'une lésion structurelle chez des patients atteints d'une polyarthrite psoriasique
US11278618B2 (en) 2014-09-10 2022-03-22 Novartis Ag Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
CN107073110A (zh) * 2014-09-10 2017-08-18 诺华股份有限公司 使用il‑17拮抗剂抑制银屑病关节炎患者的结构损伤进展
US10618967B2 (en) 2014-10-29 2020-04-14 Five Prime Therapeutics, Inc. Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
US10221244B2 (en) 2014-10-29 2019-03-05 Five Prime Therapeutics, Inc. Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
US9765147B2 (en) 2014-10-29 2017-09-19 Five Prime Therapeutics, Inc. Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer
US11566076B2 (en) 2014-10-29 2023-01-31 Five Prime Therapeutics, Inc. Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers
US10730949B2 (en) 2014-12-22 2020-08-04 Five Prime Therapeutics, Inc. Method of treating PVNS with anti-CSF1R antibodies
US10040858B2 (en) 2014-12-22 2018-08-07 Five Prime Therapeutics, Inc. Anti-CSF1R antibodies for treating PVNS
CN114249826A (zh) * 2014-12-22 2022-03-29 诺华股份有限公司 Il-17抗体中半胱氨酸残基的选择性还原
CN114249826B (zh) * 2014-12-22 2024-02-02 诺华股份有限公司 Il-17抗体中半胱氨酸残基的选择性还原
US11559583B2 (en) 2015-04-13 2023-01-24 Five Prime Therapeutics, Inc. Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer
US11421034B2 (en) 2017-09-13 2022-08-23 Five Prime Therapeutics, Inc. Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

Also Published As

Publication number Publication date
TW201307845A (zh) 2013-02-16
AR084234A1 (es) 2013-05-02

Similar Documents

Publication Publication Date Title
AU2012341081B2 (en) Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles
WO2012082573A1 (fr) Procédés prédictifs et procédés de traitement de l'arthrite en utilisant des antagonistes de l'il-17
JP7153775B2 (ja) Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
CA3116725C (fr) Secukinumab a utiliser dans le traitement de la polyarthrite psoriasique
EP3129497B1 (fr) Méthodes de traitement sélectif de l'asthme au moyen d'antagonistes de l'il-13
US20150125462A1 (en) Methods of treating ankylosing spondylitis using il-17 antagonists
US11262358B2 (en) Infiltrating immune cell proportions predict anti-TNF response in colon biopsies
JP2022031643A (ja) Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０
WO2014155278A2 (fr) Méthodes de traitement de maladies auto-immunes à l'aide d'antagonistes de l'il -17
TW201343176A (zh) 使用ｉｌ－１７拮抗劑治療乾癬性關節炎之方法
JP2022529929A (ja) α４β７阻害薬及びＩＬ－２３阻害薬の併用療法
AU2014259523B2 (en) Methods of treating psoriatic arthritis using IL-17 antagonists
US20210318334A1 (en) Materials and Methods for Improved Prediction of IGG Therapeutic Protein Exposure
US20190177407A1 (en) Methods of treating dry eye disease using tnf alpha antagonists
KR20180019125A (ko) 원발성 초점성 분절성 사구체경화증을 치료하는 방법
WO2013186541A1 (fr) Biomarqueur pour la détermination de la compatibilité d'une thérapie anti-facteur de nécrose tumorale (anti-tnf) dans le traitement de maladies auto-immunes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11799580

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11799580

Country of ref document: EP

Kind code of ref document: A1